Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
about
Options for empagliflozin in combination therapy in type 2 diabetes mellitusSodium-glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin-metforminSodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesStrategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the DiseaseLong-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysisCharacterization and identification of candiduria due to Candida species in diabetic patients.Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study.Short commentary on empagliflozin and its potential clinical impactGlucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetesCombination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin.Sodium glucose cotransporter 2 inhibition in the diabetic kidney: an updateThe potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitusDapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension.Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III StudiesReview of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.Clinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Benefits/risks of sodium-glucose co-transporter 2 inhibitor canagliflozin in women for the treatment of Type 2 diabetesDapagliflozin: a review of its use in patients with type 2 diabetes.Empagliflozin for the treatment of type 2 diabetes mellitus: An overview of safety and efficacy based on Phase 3 trials.Empagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes mellitus: a review of the evidence.Adverse Effects Associated With Newer Diabetes Therapies.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.SGLT2 Inhibitors: Benefit/Risk Balance.Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Efficacy and safety of dapagliflozin in Asian patients: A pooled analysis.Safety and Effectiveness of Tofogliflozin in Elderly Japanese Patients with Type 2 Diabetes Mellitus: a Post-Marketing Study (J-STEP/EL Study).A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin.Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: A randomized controlled trial.High glucose-mediated overexpression of ICAM-1 in human vaginal epithelial cells increases adhesion of Candida albicans.High prevalence of candiduria due to non-albicans Candida species among diabetic patients: A matter of concern?
P2860
Q26745771-0AE68493-0CAC-4535-8C83-B6634D21E45AQ26752815-923B26DF-A690-41BE-AB31-2A8C8F7D6653Q26864336-4ED37793-CEE5-4DBF-9D4F-B4A64D1F9408Q28069065-292DCF69-6C0B-4B7D-B423-2EDE6027EBEBQ30903369-DDC4DCDE-F08B-4DAC-BF7C-8C7E1B80DC99Q33767478-C07B44AE-AE51-428B-990E-1DB3052EBDD3Q33851284-B3968CA5-AD7B-496A-91A2-3256C0E21B6EQ34726376-AC5DDC9D-8C00-48C5-8CC5-9A18E022AED1Q35528797-72F7813E-DB63-4EC9-B444-B5151A90CE95Q35780861-94925EEE-C50D-4CB9-9A03-B29BCDB8B3E7Q36303346-77A692C3-57F8-4DE7-BAB6-1B666E1A49ADQ36435496-37C48917-E703-4A15-A763-556E578635EDQ36592820-DE3F8F70-21AA-40C3-AAF0-727293CCA25AQ36798684-1DD271BA-2CDE-42BB-B5D7-C63ECE85F875Q37075620-FF182030-1244-4802-BCDB-481546DFF5FFQ37340223-CDF1FDA8-9A93-44D1-8035-8C4EAE571E54Q37427304-38217E24-5CAD-4CBC-90C6-EA608A869B6FQ37588847-21FAB070-F40F-4089-8804-E518281A9953Q37722896-3DE5A09D-0422-4F0A-B101-293120752D2FQ37741752-AACC90A6-6BD9-4525-9F4A-34FC01D58B14Q38267346-2A51BF72-DD47-4337-8379-6BA1433A5166Q38353558-43E7BA02-601E-4500-A9DA-FBD18795EA52Q38364908-0660DBBC-40E6-4D15-94DF-3A28E37FAA63Q38546214-9E8DD78C-897F-4A89-9B62-5474023B932EQ38619164-525FE990-B42B-4E67-AF6B-5A49892BE82EQ38777020-9C8C5E8F-BD7F-4DA3-97EC-9B155F85C177Q38783203-052690A9-DC8B-4E83-B690-2232EACB1B0DQ38863649-63A8442C-B26F-4AD9-B0B8-2FB9D8E8C116Q38906041-F3D52B8D-7BFF-43E2-9B95-E66D5B949AC3Q38931842-27B3929C-8D84-4D31-A45A-5C47BC8769A0Q39017610-3B00E9CB-9C87-4327-B608-525CDCBA8D36Q39189383-285D686E-0657-4B9F-A37A-17239CBB7E22Q39202664-3EC2F070-E741-4CB0-9D2B-258C4F75EBD8Q39255188-240B9E7A-C747-4656-AA94-67400CDE7F3CQ39393777-72FB4EDB-2457-4204-A2DA-C6F2BA805B53Q40363925-C948CC73-B542-493D-A4C9-782C22FF1E5CQ40439768-617CE593-8FC0-455E-8D20-2B809A7E0F65Q40901927-9F1B124B-2C7A-4470-8BC8-2B0836BF27C7Q41997111-3FA51B56-A958-4DC4-BD9F-F170E51BC005Q46273464-326CC6E1-987C-4A39-849A-CBA9125958C7
P2860
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Genital and urinary tract infe ...... ologically-induced glucosuria.
@en
type
label
Genital and urinary tract infe ...... ologically-induced glucosuria.
@en
prefLabel
Genital and urinary tract infe ...... ologically-induced glucosuria.
@en
P2093
P1476
Genital and urinary tract infe ...... ologically-induced glucosuria.
@en
P2093
David Castro-Diaz
James List
Shamik Parikh
Suzanne Geerlings
Vivian Fonseca
P304
P356
10.1016/J.DIABRES.2013.12.052
P577
2014-01-08T00:00:00Z